GPC3 CAR-T cell composition, and method for preparing and using the same.

JP7875600B2Active Publication Date: 2026-06-18EUTILEX CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2022555955
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-06-24
Filing Date
2021-03-18
Publication Date
2026-06-18
Estimated Expiration
2041-03-18

Smart Images

  • Figure 0007875600000008
    Figure 0007875600000008
  • Figure 0007875600000009
    Figure 0007875600000009
  • Figure 0007875600000010
    Figure 0007875600000010
Patent Text Reader

Abstract

Provided herein are CAR-T compositions directed against GPC3, including chimeric receptors, and engineered immune cells against GPC3. The present disclosure also provides vectors, compositions, and therapeutic methods using GPC3 antigen-binding molecules and engineered immune cells. The GPC3 CAR compositions provided herein can be used to treat certain cancers.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nucleic acid encoding gpc3 chimeric antigen receptor protein and t lymphocyte expressing gpc3 chimeric antigen receptor protein

    JP2016523518A

  • Glypican-3-specific chimeric antigen receptor for adoptive immunotherapy

    JP2017529851A

  • Chimeric Antigen Receptor

    JP2019530431A

  • GPC3-targeted therapeutic agent administered to patient in whom GPC3-targetd therapeutic ag

    WO2017002934A1

  • Anti-GPC3 single-chain antibody-containing car

    WO2020017479A1